Table 2 Demographic, clinical, and imaging data for all participants in this study
From: Heart fatty acid binding protein and Aβ-associated Alzheimer’s neurodegeneration
HC (n = 90) | MCI (n = 139) | AD (n = 66) | |
|---|---|---|---|
Age, Mean (SE) | 76.0 (0.6) | 75.1 (0.7) | 75.4 (0.9) |
Female, % | 51 | 33 | 41 |
Education Years, Mean (SE) | 15.6 (0.3) | 16.1 (0.2) | 15.1 (0.4) |
MMSE, Mean (SE) | 29.1 (0.1) | 26.7 (0.1) | 23.4 (0.2) |
CDR-SB, Mean (SE) | 0.03 (0.01) | 1.5 (0.07) | 4.2 (0.2) |
APOE ϵ4 carriers (%) | 24 | 54 | 71 |
CSF H-FABP level (ng/ml), Mean (SE) | 0.38 (0.03) | 0.54 (0.02) | 0.58 (0.03) |
CSF Aβ1–42 level (pg/ml), Mean (SE) | 207.8 (5.6) | 157.5 (4.1) | 141.5 (2.6) |
CSF p-tau181p level (pg/ml), Mean (SE) | 24.7 (1.4) | 36.8 (1.3) | 41.7 (2.6) |
Entorhinal Cortex APC, Mean (SE) | -0.8 (0.1) | -2.4 (0.1) | -2.9 (0.2) |
AD-vulnerable ROI APC, Mean (SE) | -1.1 (0.1) | -3.2 (0.2) | -3.9 (0.3) |